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Laparoscopic repeated pancreatectomy for 
isolated local recurrence in remnant pancreas following 
laparoscopic radical pancreatectomy for 
pancreatic ductal adenocarcinoma: Two cases report
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Typical treatment for recurrent pancreatic cancer is potent chemotherapy or chemoradiotherapy. However, recent clin-
ical investigations suggest a potential therapeutic role of local resection in recurrent pancreatic cancer. Based on accu-
mulating surgical experience of minimally invasive pancreatectomy, we report cases of two patients who underwent 
successful laparoscopic re-resection of isolated local recurrence following laparoscopic radical pancreatectomy for pan-
creatic cancer. (Ann Hepatobiliary Pancreat Surg 2020;24:542-546)
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INTRODUCTION
Recurrent pancreatic cancer is generally treated with 
potent chemotherapy or chemoradiotherapy. However, re-
cent clinical investigations suggest a potential oncologic 
role of local resection in recurrent pancreatic cancer. 
Groot et al.1 performed a systematic review on isolated 
local recurrence of pancreatic cancer. Based on eight pub-
lished studies, including 100 patients who underwent 
re-resection of recurrent pancreatic cancer, they concluded 
that local re-resection of recurrent pancreatic could be fea-
sible, safe, and effective in selected patients. They demon-
strated that postoperative morbidity and mortality were 
29% and 1%, respectively. Median survival was much 
higher (32 months) than other treatment modalities, such 
as chemotherapy (19 months) or radiotherapy (16 months).
Based on accumulating surgical experience, laparo-
scopic distal pancreatectomy2,3 and laparoscopic pan-
creaticoduodenectomy4,5 are regarded as safe potential op-
tions in well-selected pancreatic cancer patients. Herein, 
we report two patients who underwent successful repeat 
laparoscopic pancreatectomy for isolated local recurrence 




A 68-year-old Korean man was found to have recurrent 
pancreatic cancer on follow-up computed tomography 
(CT). He had a medical history of hypertension and dia-
betes, and was a hepatitis C virus carrier. He also under-
went laparoscopic small bowel segmental resection for a 
gastrointestinal stromal tumor (ileum) in 2012, as well as 
right posterior sectionectomy for hepatocellular carcinoma 
in 2015. During regular follow-up, pancreatic tail cancer 
(pT3N0) was incidentally detected, and he underwent lap-
aroscopic radical distal pancreatectomy with splenectomy 
on June 7, 2016. The pathologic result was ductal ad-
enocarcinoma, well-differentiated (pT3N0M0, stage IIA). 
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Fig. 1. Perioperative findings. 
Recurrent pancreatic cancer was 
noted on remnant pancreas (A). 
The pancreatic neck was fully 
mobilized from the SMV-PV- 
SV confluence (B). Combined gas-
tric wedge resection (thin white 
arrow) was performed (C). The 
splenic artery was dissected and 
resected by endo-GIA (yellow 
arrow), and the splenic vein was 
also ligated (thick arrow, D). T, 
tumor area in remnant pancreas; 
P, pancreatic neck; SMV, supe-
rior mesenteric vein; SV, sple-
nic vein; S, stomach; CHA, com-
mon hepatic artery.
The patient received six cycles of gemcitabine as adjuvant 
chemotherapy from July 4 to December 19, 2016. 
Physical examination revealed no specific findings. 
Tumor marker CA 19-9 was elevated (217.0 U/ml). 
Follow-up CT (April 23, 2018) showed a 2.3-cm low at-
tenuating lesion at the pancreas resection margin, suggest-
ing local tumor recurrence. Further evaluation with 
PET-CT suggested no metastatic lesions; therefore, the 
surgical option for local recurrence was selected over 
chemotherapy.
The patient underwent laparoscopic segmental resection 
of the pancreatic neck on May 23, 2018. There were mild 
to moderate adhesions. Recurrent tumor abutted the poste-
rior wall of the stomach, suggesting cancer invasion. 
Gastric wedge resection was done by endo-GIA in order 
to achieve en-bloc resection of the cancer. Finally, the 
proximal portion of the remnant splenic artery was dis-
sected and resected by endo-GIA (Fig. 1).
The tumor was recurrent pancreatic ductal ad-
enocarcinoma with tumor size of 2.4 cm in maximum 
diameter. Lymphovascular invasion was noted without 
perineural invasion. All resection margins, including pan-
creatic duct and circumferential margin, were negative for 
carcinoma cells. In total, eight lymph nodes were re-
trieved and all were negative. The patient was discharged 
seven days postoperatively. The oncology department 
gave the patient 13 cycles of gemcitabine and abraxane 
as postoperative adjuvant chemotherapy. Chemotherapy 
was stopped on November 8, 2018, due to acute kidney 
injury. There were no definite metastatic lesions in the ab-
domen on follow-up CT 1 year after surgery. 
Case 2
A 65-year-old Korean woman was admitted to the hos-
pital due to isolated local recurrence in the remnant 
pancreas. She previously underwent laparoscopic pan-
creaticoduodenectomy with combined segmental resection 
of the SMV-SV-PV confluence on April 4, 2018. The pa-
tient received postoperative adjuvant chemotherapy for six 
months with a gemcitabine regimen. During her regular 
follow-up, local recurrence near the previous pan-
creaticojejunostomy site was detected. Follow-up CT with 
pancreas dynamic spiral 3D showed a new suspicious 
mass at the pancreaticojejunostomy site. Preoperative tu-
mor markers (CEA, 8.66 ng/ml, and CA19-9, 35.2 U/ml) 
were checked. No further progression was noted during 
adjuvant chemotherapy. Therefore, she decided to undergo 
laparoscopic completion total pancreatectomy on May 29, 
2019. As a result of the previous laparoscopic approach, 
there were moderate adhesions in the abdominal cavity 
and around the pancreaticojejunostomy sites. 
To facilitate the surgical procedure, the pancreatico-
splenic ligament was divided using endo-GIA. The jeju-
num was dissected and divided near the previous hep-
aticojejunostomy site. Remnant pancreas was dissected, 
but it was challenging to dissect from the superior mesen-
teric artery and the splenic artery due to severe in-
flammatory changes and tumor infiltration. Vascular en-
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Fig. 2. Perioperative findings. 
Recurrent pancreatic cancer at 
the pancreaticojejunostomy (PJ) 
site (white arrow, A). The jeju-
num was resected near PJ site 
(B). Tumor was dissected from 
the superior mesenteric artery. 
The splenic artery was ligated 
with vascular endo GIA (yellow 
arrow, C). Gross findings of re-
current tumor at the PJ site (white 
arrow, D). CHA, common hepatic 
artery; SA, splenic artery; PJ, pre-
vious pancreaticojejunostomy site; 
J, proximal jejunum after resec-
ting previous Roux-en-Y limb 
for PJ; SMA, superior mesenteric 
artery.
do-GIA was applied to control the splenic artery. The to-
tal operation time was 270 min, and the estimated blood 
loss was 650 ml. Pathological examination revealed re-
current adenocarcinoma involving the pancreas and small 
bowel. The tumor size was 1.7×1.5 cm. Lymphovascular 
invasion was noted without perineural invasion. The pos-
terior margin of the pancreas showed extension of the 
carcinoma. Other resection margins, including the anterior 
pancreas, lateral small bowel, and spleen, were free from 
carcinoma cells. The patient was discharged 12 days 
postoperatively. Radiotherapy and adjuvant chemotherapy 
were planned (Fig. 2).
DISCUSSION
Regarding long-term oncologic outcomes of repeat pan-
createctomy for isolated local recurrence of pancreatic 
cancer, Yamada et al.6 reported 114 patients with remnant 
pancreatic cancer after initial pancreatectomy. A total of 
90 patients underwent repeat pancreatectomy and median 
survival was 26 months, superior to that of non-resected 
patients (HR: 0.56, p=0.012). Hashimoto et al.7 reviewed 
12 published studies about recurrent pancreatic cancer in 
remnant pancreas following initial pancreatectomy, show-
ing overall survival after repeat pancreatectomy for rem-
nant pancreatic cancer of 14 to 35.5 months, which was 
longer than that of unresectable pancreatic cancer patients 
in recent studies.8,9 In addition, Zhou et al.10 performed 
pooled analysis of the second pancreatectomy for re-
current pancreatic ductal adenocarcinoma. They retrieved 
55 patients from 19 published articles and investigated 
long-term overall survival. It was found that 1-, 3-, and 
5-year overall survival rates after repeat pancreatectomy 
were 82.2%, 49.2%, and 40.6%, respectively, suggesting 
a potential role of repeat pancreatectomy for isolated re-
current pancreatic cancer in remnant pancreas.
Only a few cases of laparoscopic repeat pancreatectomy 
have been published, and only two reported the technical 
feasibility of laparoscopic repeat pancreatectomy after ini-
tial pancreatectomy (Table 1). Sunagawa et al.11 reported 
the first case successfully treated by laparoscopic com-
pletion total pancreatectomy for newly developed pancre-
atic cancer in remnant pancreas after laparoscopic pan-
creaticoduodenectomy for distal bile duct cancer. Recent-
ly, Nakagawa et al.12 also published a case of laparoscopic 
pancreaticoduodenectomy for remnant pancreatic re-
currence after laparoscopic distal pancreatectomy and hep-
atectomy for leiomyosarcoma. In this report, pancreati-
cojejunostomy was performed through a small epigastric 
wound where the surgical specimen was removed. 
To the best of our knowledge, the present two cases 
are the first to show the technical feasibility and safety 
of laparoscopic repeat pancreatectomy for recurrent pan-
creatic ductal adenocarcinoma in remnant pancreas after 
initial laparoscopic radical pancreatectomy for primary 
pancreatic cancer. Minimally invasive pancreatectomy in 
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Table 1. Cases reporting technical feasibility of laparoscopic repeated pancreatectomy













Sunakawa et al., 
2014
1 72 F BDC PPPD 18 CTP 1200 462 14 No NA
Nagakawa et al., 
2019
1 67 F LMS DPS 10 SSPPD 50 274 13 No 16 months, alive 
Present, 2019 1 68 M PC DPS 23 PR 200 290 7 No 22, alive, NED
2 65 F PC PPPD 11 CTP 650 270 12 No 10 months, alive, NED 
BDC, bile duct cancer; LMS, leiomyosarcoma; PC, pancreatic cancer; PPPD, pylorus preserving pancreaticoduodenectomy; 
SSPPD, subtotal stomach-preserving pancreaticoduodenectomy; PR, partial pancreatic resection; CTP, completion total pan-
createctomy; NED, no evidence of disease; NA, missing value; EBL, estimated blood loss; OP, operation; OT, operation time; 
LOH, length of hospital stay
pancreatic cancer remains controversial. However, our re-
cent experiences3,5 and meta-analysis2,4 suggest the techni-
cal and oncological safety of a minimally invasive ap-
proach to well-selected pancreatic cancer. 
These are our rationales for minimally invasive radical 
pancreatectomy for pancreatic cancer: 1) Laparoscopic 
margin-negative resection without ruining oncologic prin-
ciple is quite feasible. 2) Usually, pancreatic head cancer 
is associated with a hard pancreas with a relatively large 
pancreatic duct, which can be related to a rare incidence 
of postoperative pancreatic fistula. 3) Postoperative patient 
recovery appears to be quite smooth due to the benefit 
of minimally invasive surgery, 4) which can provide good 
clinical conditions for subsequent postoperative adjuvant 
chemotherapy. 5) Finally, postoperative adhesions are 
quite limited, which is appropriate for unexpected reoper-
ation, including repeat pancreatectomy. 
Further research is needed to establish the indications 
for minimally invasive pancreatectomy for pancreatic 
cancer. In addition, well-designed clinical investigations 
and an expert consensus are needed for developing man-
agement guidelines toward minimally invasive radical 
pancreatectomy for resectable pancreatic cancer and re-
peat pancreatectomy for isolated local recurrence of pan-
creatic cancer in remnant pancreas.
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